Stifel holds TransMedics stock at Hold amid competition concerns

Published on 10/18/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stifel kept Hold on TransMedics stock at USD 65.00 on October 15, 2026. Q2 revenue reached USD 189.9 million, up 21.00 percent.

Analyst caution and growth

Stifel maintained a Hold rating and a USD 65.00 price target for TransMedics on October 15, 2026.
TransMedics reported USD 189.9 million in second-quarter 2026 revenue, up 21.00 percent year over year.
Canaccord lowered its target from USD 95.00 to USD 94.00 on October 13, 2026.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group (ISIN US89377M1099) had its Hold rating reiterated by Stifel on October 15, 2026, with a USD 65.00 price target, according to Investing.com. The firm identified competition as a potential multi-year pressure on the medical technology company.

Targets diverge from growth

The analyst view is not uniform. Canaccord Genuity lowered its target from USD 95.00 to USD 94.00 while retaining a Buy rating on October 13, 2026, MarketBeat reported. Barclays had initiated coverage with an Overweight rating and a USD 120.00 target on October 7, 2026, the same report said.

The underlying growth figures remain substantial but profitability is the counterweight. For the second quarter of 2026, TransMedics reported revenue of USD 189.9 million, up 21.00 percent from USD 157.4 million a year earlier. Net income fell to USD 14.7 million from USD 34.9 million, while adjusted diluted earnings per share declined to USD 0.44 from USD 0.92, according to the company filing carried by MarketWatch.

What does competition mean for growth?

Stifel's answer is visible in its forecast. The firm estimated third-quarter 2026 revenue of USD 185 million to USD 190 million, compared with a Street estimate of USD 178 million, while maintaining a Hold rating because of longer-term competitive risks, Investing.com reported. The comparison leaves investors weighing near-term sales execution against the durability of TransMedics' margin profile.

Three dated signals for TMDX

On August 4, 2026, TransMedics reported USD 189.9 million in second-quarter revenue and raised its full-year 2026 revenue guidance to USD 737 million to USD 757 million, according to MarketWatch. On October 7, 2026, Barclays began coverage with a USD 120.00 target, and on October 15, 2026, Stifel retained Hold with a USD 65.00 target, as MarketBeat reported.

Market value and yearly range

TransMedics had a market capitalization of USD 2.5 billion on October 16, 2026. Its 52-week range ran from USD 60.10 to USD 156.00, placing the company in a valuation debate shaped by both revenue expansion and earnings pressure.

The further course of trading is shown by the continuously updated real-time quote of TransMedics Group stock.